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Stem cell scientists trying to reach patients often lack the multidisciplinary skills needed to overcome
complex regulatory barriers and may feel deterred from pursuing clinical implementation. In order to help
bridge this gap, we offer a European perspective based on our hands-on experience at the Andalusian Initia-
tive for Advanced Therapies.Advanced therapies constitute one of
the most complex organizational and
regulatory areas currently approached
by clinical research in order to explore
new therapeutic applications. Basic
scientists and clinicians trying to imple-
ment stem cell science into clinical
practice may feel overwhelmed by the
apparently endless regulatory require-
ments that apply. In this article we
review, from a European perspective,
practical issues that must be confronted
in order to move from ‘‘proof of concept’’
studies in animal models into human
subjects. In trying to answer what steps
are needed to move stem cells into
clinical practice, several review articles,
including a recent series on stem cell
‘‘roadmap to the clinic’’ (Daley, 2010),
have taken different approaches in
covering the topic (i.e., define appro-
priate cell source, best expansion, purifi-
cation, and delivery methods, etc.).
Others have thoroughly reviewed good
manufacturing practice (GMP) as ap-
plied to stem cells and their derivatives
(Ahrlund-Richter et al., 2009). We offer
a complementary perspective by sharing
our experience at the Andalusian Initia-
tive for Advanced Therapies in Spain,
a publicly funded entity that has been
established to bridge the gap between
academic and clinical researchers and
the translation of their findings to widely
distributed therapeutic interventions.
We briefly outline the basic definitions
for cell products and clinical protocols,
followed by a focused discussion of
the relevant organizational actions to
be undertaken by interested research
institutions.508 Cell Stem Cell 6, June 4, 2010 ª2010 ElsDefinition of Advanced Therapy
Medicinal Products
Advanced therapies were classified as
such by two European Directives (2003/
63/EC and 2009/120/EC) and Regulation
(EC) No. 1394/2007 of the EuropeanParlia-
ment and of the Council. They defined
‘‘advanced therapy medicinal products’’
(ATMPs) into three main types: (1) gene
therapy, (2) somatic cell therapy, and (3)
tissue engineered products. Cells or
tissues shall be considered ‘‘engineered’’
if they fulfill at least one of the following
conditions: (a) the cells or tissues have
been subject to substantial manipulation,
so that biological characteristics, physio-
logical functions, or structural properties
relevant for the intended regeneration,
repair, or replacement are achieved. For
these purposes, the manipulations listed
in Annex I to the Regulation, in particular,
shall not be considered as substantial
manipulations (e.g., cell separation, con-
centration, or purification); or (b) the cells
or tissues are not intended to be used for
the same essential function in the recipient
as in the donor (Figure S1 available online).
Importantly, it can be ascertained
from the definitions above that not all cells
that go into patients will be classified as
ATMPs: uncultured cells used for the
same essential function in the recipient
as in the donor, will be regulated in a
different manner, i.e., as a cellular trans-
plant (Directives 2004/23/EC and 2006/
17/EC).
Cells as Medicinal Products:
Manufacturing Aspects
Oncewehavedetermined that a particular
cellular product lies within the ATMP cate-evier Inc.gory, regardless of it being investigational
(i.e., a drug to be used in clinical trials
and not yet authorized for marketing as
such), production of the cells that will go
into patients must comply with good
manufacturing practice (GMP) for medic-
inal products. Implementation of GMP in
cell manufacturing processes substan-
tially increases production costs. How-
ever, regulatory agencies are unlikely to
be dissuaded from requiring GMP imple-
mentation on the basis of monetary argu-
ments, because patient safety and law
enforcement are, and should be, their
primary considerations. It is therefore
important that stem cell scientists are
aware of the intricacies of GMP imple-
mentation before initiating full-fledged
translational programs.
Typical regulatory concerns surround-
ing the application of cellular components
are product safety, characterization of the
cells, and characterization and control of
their manufacturing process. With regard
to safety, cell donors must be carefully
screened and the cellular product, once
expanded in the GMPproduction facilities
through master and working cell banks,
must be checked by several standard-
ized tests (viability, sterility, adventitious
agents, genetic stability/tumorigenicity,
pyrogenicity, mycoplasma infection, etc.).
Cell products will usually have to be
defined as for identity, purity, potency,
stability, and viability.
Clinical Research with ATMPs
Before administration into humans, both
biological activity and toxicity of the
investigational medicinal product must
be tested in a relevant animal model
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(GLP). Researchers must then seek
approval of an institutional review board
(IRB) for all centers involved in the clinical
trial as well as an authorization from the
national regulatory agencies of the coun-
tries where patients will be recruited, irre-
spective of their nationalities. In order to
guarantee respect for human subject
rights, ensure data quality, and steer clear
of avoidable errors, European Directives
2001/20/EC and 2005/28/EC on good
clinical practice (GCP) and associated
guidelines (e.g., CPMP/ICH/135/95) must
be followed. Likewise, and specifically for
the clinical translation of stem cells, the
ISSCR Guidelines offer a good starting
point (Hyun et al., 2008). Once the clinical
trial is authorized and patient recruitment
has started, the sponsor has a legal
requirement to communicate to the regu-
latory authorities any suspected unex-
pected serious adverse reactions. The
sponsor’s duties also include ensuring
that there is an insurance policy in place
to cover any liability, that recruitment
of subjects is done after appropriate
informed consent, and that approval of
medicinal product batches for release
conforms to specifications.
End of the Road: Marketing
Authorization, Distribution, and
Pharmacovigilance of ATMPs
If the regulatory bodies determine that
quality, safety, and efficacy of an ATMP
are sufficiently established through
successful clinical phases, then the next
step is to apply for marketing authoriza-
tion. This step must be done through
a centralized procedure at the European
Medicines Agency (EMA), and approval
would bestow Europe-wide commerciali-
zation rights. For this reason, the set
requirements are usually even more strin-
gent than those expected of clinical trial
applications, because the number of
candidate patients may be enormous,
especially in the case of highly prevalent
conditions. The requisites and procedure
for commercialization of ATMPs are
beyond the scope of this review and are
primarily relevant for pharmaceutical
companies. At the moment only one
ATMP has been grantedmarketing autho-
rization at the EMA, an industrial product
based on autologous chondrocytes
expanded for cartilage regeneration. Of
note, some European countries permitexceptions to this authorization rule de-
pending on the nature of the medicinal
product, be it industrial or otherwise.
This exemption is based on the exclusion
defined by Regulation 1394/2007 for
ATMPs that are prepared on a nonroutine
basis and only as a custom-made product
for an individual patient. We would like to
encourage national authorities to
consider a more flexible procedure than
the marketing authorization process that
would allow certain nonindustrially manu-
factured medicinal products to be intro-
duced into clinical practice. Such prod-
ucts would include those that can’t be
commercialized because they are more
similar to a service than to a product,
and would still need to meet requirements
for quality, safety, and efficacy. On the
other hand, and in order to give small
and medium-sized enterprises (SMEs)
an incentive to conduct quality and
nonclinical studies on ATMPs, a recent
regulation has come into force (No. 668/
2009). Accordingly, the EMA Committee
for Advanced Therapies (CAT) has pub-
lished a related guideline on the minimum
quality and nonclinical data required for
certification of ATMPs (EMEA/CAT/
486831/2008/corr). Even though the certi-
fication provided is not legally binding,
this system aims at facilitating the evalua-
tion of any future application for clinical
trials and marketing authorization appli-
cation based on the same data. In our
view, it would be of great help to allow
a similar certification to hospitals and
academic researchers at nonprofit institu-
tions, irrespective of the size of their work-
force (be it SME or not).
Finally, the safety oversight of investi-
gational medicinal products and pharma-
covigilance is a key aspect of all research
with ATMPs. These products are consid-
ered relatively ‘‘high risk’’ and regulatory
authorities will require tight safety follow-
up of ATMP-treated patients, both in
clinical trials and after marketing authori-
zation (Directive 2004/27/EC).
ATMP Development from Scratch
Medicinal product development, from
discovery to marketing authorization, is
thus a costly, lengthy, highly regulated,
and high-risk process (Figure 1). As such,
it is difficult to approach this goal and
achieve a reasonable success rate in
reaching the market, leaving medicinal
product development predominantly inCell Stem Cthe hands of big pharmaceutical compa-
nies that have the financial and human
capacities to invest the enormous
resources required (Kola and Landis,
2004). Unfortunately, stem cell science
has attracted relatively little interest from
big pharma to date (McKernan et al.,
2010, this issue of Cell Stem Cell). Oft-
quoted reasons are general uncertainties
with regard to therapeutic promise of
ATMPs, high production costs, and
extreme logistical complexity because of
specific characteristics of these products,
such as their generally short shelf life, rela-
tively long-term investment revenues, and
differing international regulatory climates.
It is therefore compulsory to implement
some sort of bridge between promising
basic stem cell science results and the
pharmaceutical industry (Trounson et al.,
2010, this issue of Cell Stem Cell). Such
a bridge will probably involve solid
management of intellectual property
rights, demonstration of success through
early-phase clinical trials, and technolog-
ical transfer to interested third parties.
Several small biotech companies are
filling this gap world-wide with varying
success (Lysaght et al., 2008).
Bridging the Gap in Andalusia
As a publicly funded alternative, in 2008
the Andalusian Government created
what is now known as the Andalusian
Initiative for Advanced Therapies. Andalu-
sia is the biggest region in Spain, with
nearly 8.5 million inhabitants. With an
autonomous government since 1981 and
a 100% publicly funded healthcare
system, with universal coverage, Andalu-
sia has pioneered stem cell legislation in
Spain (Law 7/2003 on research with
embryonic stem cells and Law 1/2007
on cellular reprogramming). The Initiative
draws up plans and tailors the resources
to promote research in the field of
advanced therapies in Andalusia and to
transfer basic research into clinical prac-
tice through the forging of alliances
among academia, research institutions,
hospitals, patient associations, and the
biotech and pharmaceutical industries.
Although mainly financed at a regional
level, with 84MV allocated to projects
and research infrastructures in advanced
therapies in the last 6 years, the Initiative
is also supported by Spanish National
funding agencies. The budget allocated
for the next 6 year strategic planell 6, June 4, 2010 ª2010 Elsevier Inc. 509
Figure 1. Andalusian Initiative Support for ATMP Development and Relevant Regulatory Facts for Each Stage
The scheme depicts the five stages of typical medicinal product development and the specific support given by the Andalusian Initiative. It starts with basic in vitro
studies, followed by nonclinical research in animal models to understand toxicity and biological activity of the medicinal product. The latter should be performed
by following good laboratory practice (GLP). From this early phase throughout clinical trials to evaluate safety and efficacy, the investigational medicinal product
should be produced under goodmanufacturing practice (GMP) and infused to patients under good clinical practice (GCP). In Europe, national regulatory agencies
will be responsible for approval of all these stages. In an ideal situation, the final step ofmarketing authorizationwill be done through a centralized procedure at the
European Medicines Agency and the registered medicinal product will be ready for commercialization under good distribution practice (GDP).
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not included within these figures).
Although other countries such as Brazil
and Korea have committed public funds
to clinical trials of stem cell treatments
and multiple US states, led by California,
are also working in that direction, the
Andalusian Initiative offers a distinct,
major translational focus. That is, in addi-
tion to building research centers and
funding basic research grants for
advanced therapies, as other regional
administrations have done elsewhere in
the world (Daniels et al., 2006), our organi-
zation provides all the support required by
basic and clinical researchers for trans-
lating research, acting as sponsors of
noncommercial clinical trials driven by
investigators based at the local research
institutions and hospitals. This model
was designed with the intention to facili-
tate clinical research and innovation
within the public health system.
Some cellular therapies that have no
manufacturing process involved (and spe-
cifically those ‘‘nonsubstantially manipu-510 Cell Stem Cell 6, June 4, 2010 ª2010 Elslated’’ cell protocols that do not fit into
the ‘‘transplant’’ classification) do not
attract significant commercial interest,
and it is therefore difficult to develop
a business model around them. As
a publicly funded Initiative especially
accountable to our Regional Health
Ministry and focused on population health
improvement and innovation within the
healthcare system, our particular interest
is to develop new therapeutic approaches
and make them available to the general
population. Based on this mandate, our
efforts aim to promote the development
of new advanced therapies not only out
of commercial interests but also purely
as a service. Likewise, when manufac-
tured cells that lie within ATMP category
are developed, intellectual property will
be handed to interested companies
through transparent licensing or partner-
ship agreements, although some of the
reimbursement will be handed back to
the regional government under different
formulae as legislated (Andalusian
Science and Knowledge Law 16/2007).evier Inc.Furthermore, support comes not only in
the form of financing, but also with imple-
mentation of complementary expertise.
Success of this organizational model is
evidenced by the construction of multiple
public GMP facilities for cell production
within Andalusia and the authorization of
several Phase I/II clinical trials by Spanish
regulatory authorities in the areas of cardi-
ology, neurology, immunology, peripheral
vasculardisease,andhepatic regeneration
(more information available at http://www.
juntadeandalucia.es/terapiasavanzadas/).
A Model to Support Researchers
Interested in Therapeutic
Development
As an Initiative promoted by the Regional
Government of Andalusia, our work
comprises all the steps between the
generation of knowledge and knowledge
transfer with a special emphasis on the
development of new therapies. For that
reason, over the last few years we have
pushed to build a cluster of research
centers, biobanks, and GMP facilities.
Table 1. Main Support Activities of the Andalusian Initiative for Advanced Therapies
Related to Clinical Research
Assessment on the Regulatory Agencies’ Requirements
Nonclinical experimental design: pharmacodynamic proof of concept, biodistribution, dose,
toxicity, immunogenicity, tumorigenicity studies
Product safety, characterization of the cells (identity, purity, potency, stability, and viability), and
characterization and control of their manufacturing process
Design and Implementation of GMP-Compliant Cell Production Laboratories
Design technical installations and equipment according to homogenous standards
Supervise the construction, development, and maintenance of GMP facilities
Prepare relevant documentation for regulatory approval of GMP facilities, quality management
systems, validation of equipment and installations, audits of the National Medicines Agency
Hire and train laboratory personnel
Promotion and Development of Investigational Medicinal Products
Encourage collaboration between basic and clinical researchers to help design clinical trials
Negotiate insurance policies and agreements with hospitals and clinicians: zero cost for
researchers involved
Prepare IMPDs and handle authorization paperwork required by IRBs and National Medicines
Agency
Advise on product characterization and quality controls
Perform the administrative release of medicinal batches
Supervise monitoring process and results analysis
Perform safety vigilance of the IMP (in agreement with Andalusian Centre for
Pharmacovigilance)
Financial Support
Help with grant applications and direct financial support
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policy that includes direct recruitment of
researchers through competitive calls,
training and return programs, andmobility
programs. We have also designed our
own training program for manufacturing
and clinical research on advanced thera-
pies that includes practical training
modules held under real conditions at
a GMP facility built for training purposes.
This modular training program covers
materials intended for all personnel in-
volved in translational work, including
technical directors, heads of manu-
facturing, quality control and quality
assurance workers, technicians, and clin-
ical researchers.
Moreover, the Initiative was set up as
a comprehensive support hub to develop
clinical research, and in particular to
promote noncommercial clinical trials.
To that end, we act as sponsors, providi-
ng the support that our researchers and
clinicians need and that would usually be
provided by the pharmaceutical industry.
Our organization has built GMP facilities
in multiple research centers and hospi-
tals. Most of the clinicians work for our
health service, but an increasing numberof clinicians based at other health
services collaborate with us in multicenter
clinical trials. In summary, we currently
support the construction and accredita-
tion of a network of clean rooms, the
development of investigational medicinal
products, and the design and implemen-
tation of clinical trials (Table 1). In the
case of the latter, our support begins
with a regulatory assessment during
preclinical development, followed by
promotion of collaborations between
basic and clinical researchers, and
extends all the way to monitoring the
safety of the resulting investigational
medicinal products.
Concluding Remarks
Our experience dealing with regulatory
authorities in order to authorize clinical
trials with ATMPs has been quite remark-
able: in the last few years, we have moved
from a do-it-yourself approach, where
almost no one was in a position to issue
specific recommendations for a particular
ATMP application, to a fast-moving field
with a constantly evolving regulatory land-
scape that scientists and regulators alike
find difficult to navigate. Several of theCell Stem Cregulatory advances, including the estab-
lishment of the regulatory agencies them-
selves (Wax, 1995), have come about in
response to unintended side effects of
novel therapies. We are also aware of
how adverse events in early gene therapy
clinical trials caused a major setback in
the field (Wilson, 2009). However, the
pitfalls encountered because of inser-
tional mutagenesis do not actually reflect
the predominantly successful record of
these therapies to date, which indicates
that gene therapy has a favorable risk-
benefit profile (Aiuti and Roncarolo,
2009). For obvious reasons, every clinical
trial will carry an associated risk, because
of the investigational nature of these
efforts. However, it is in everybody’s
interest to ensure that the field avoids
any major setbacks that arise from novel
ATMP clinical trials. We can only
encourage researchers and clinicians to
contact regulators at an early stage of
ATMP development (as early as possible)
and to make use of regulatory mecha-
nisms such as orphan drug designation
(if pertinent) that will help alleviate the
high costs associated to medicinal
product development.
Our intention has been to convey that
although seemingly complicated, the
gap between stem cell science and thera-
pies is certainly bridgeable. Only through
concerted effort with regulators can
publicly financed nonprofit institutions
shoulder the enormous logistical and
monetary burden required for full-fledged
ATMP development. However, only by
applying the highest quality, safety, and
efficacy standards, can we anticipate
that the stem cell field will move toward
clinical translation at a steady pace.
In showing here the efforts made to
design a unique model in a public health
system to help the translation of research
into clinics, our particular interest was to
collaborate in the development of new
therapeutic approaches, to find alterna-
tives for diseases for which there is
currently no cure, and tomake them avail-
able to the general population.
Other research institutions might want
to follow our organizational model, act-
ing as sponsors of clinical trials and
giving comprehensive support to both
researchers and clinicians where needed.
In doing so, we hope to expand the notion
that this particular bridge may and should
be crossed more often. Rather thanell 6, June 4, 2010 ª2010 Elsevier Inc. 511
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researchers, in our experience it is a
worthwhile investment to build a multidis-
ciplinary and skilled support team, as
appropriate to develop this special sort
of medicinal product and convert them
into therapies.
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